WU-CART-007 anti-CD7 CAR-T for relapsed or MRD-positive T-cell ALL and lymphoblastic lymphoma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

WU-CART-007 is an allogeneic anti-CD7 CAR-T cell therapy designed to target T-cell malignancies. This Phase 2, single-arm, multi-center, open-label trial enrolls patients aged six months and older with relapsed/refractory T-ALL or T-LBL or those in remission but remaining MRD positive. Participants receive a WU-CART-007 infusion at one of the study centers and are followed for response, MRD status, durability of remission, and safety, including CAR-T–related toxicities and graft-versus-host disease. The primary goal is to see how often the therapy induces complete MRD-negative remissions, with secondary endpoints focused on durability and adverse events.

Why it matters

Who can join: the full rules

Key Inclusion Criteria:

* Disease Criteria: Evidence of T-ALL or T-LBL, as defined by World Health Organization (WHO) classification, and either relapse/refractory or MRD positive
* Age: Lower age limit of ≥ 6 months; adequate organ function
* Eastern Cooperative Oncology Group (ECOG) 0 or 1/Karnofsky Performance Status 70 and above at Screening.

Key Exclusion Criteria:

* Prior treatment with any anti-CD7 therapy.
* Patients with decompensated hemolytic anemia.
* Presence of Grade 2 to 4 acute or extensive chronic GvHD requiring systemic immunosuppression. Grade 1 GvHD not requiring immunosuppression or Grade 2 skin GvHD if treated with topical therapy only are acceptable.

Where it's running

• City of Hope
  Duarte, California, United States Recruiting
• Children's Hospital Los Angeles
  Los Angeles, California, United States Recruiting
• Colorado Blood Cancer Institute
  Denver, Colorado, United States Recruiting
• Children's National Hospital
  Washington D.C., District of Columbia, United States Recruiting
• H. Lee Moffitt Cancer Center and Research Institute Hospital
  Tampa, Florida, United States Recruiting
• Children's Hospital of Atlanta
  Atlanta, Georgia, United States Recruiting

Study contacts

• Study coordinator: Allotera Therapeutics Clinical Trials Clinical Trials
• Email: clinicaltrials@alloteratx.com
• Phone: 314-501-1968

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Isometric wall squat exercise to lower blood pressure in adults with hypertension

  We’re testing whether doing isometric wall squats at home for 12 weeks can help lower 24-hour blood pressure in adults with essential hypertension.

  Recruiting Korea University Guro Hospital · Seoul, Seoul · NCT07868822

• Strength Training for Kids with Acute Lymphoblastic Leukemia and Lymphoblastic L lymphoma

  Researchers are testing a structured strength-training program for children and teens recently diagnosed with ALL or lymphoblastic lymphoma to see if it helps with weight gain and physical function during treatment.

  Recruiting UNC Lineberger Comprehensive Cancer Center · Chapel Hill, North Carolina · NCT07634653

• Ring-style blood pressure bracelet test compared with 24-hour monitoring in people with HFrEF

  A ring-type blood pressure device is being tested to see if its 24-hour readings match those from standard ambulatory monitoring in adults with heart failure and reduced ejection fraction.

  Recruiting Keimyung University Dongsan Medical Center · Daegu · NCT07626879

• First-in-human testing of 4A10 for relapsed or hard-to-treat ALL and lymphoblastic lymphoma

  This early-stage trial tests a new antibody therapy called 4A10 in patients with relapsed or hard-to-treat acute lymphoblastic leukemia or lymphoblastic lymphoma to see if it is safe and how the body handles it.

  Recruiting at 5 sites Phase 1 Allterum Therapeutics, Inc · Aurora, Colorado and 6 other locations · NCT07586618

• TSLPR-CART therapy for CRLF2-R/TSLPR–expressing B-ALL in adults

  This study tests a CAR T-cell treatment called TSLPR-CART in adults whose B-ALL cells overexpress TSLPR and have not responded to standard therapy.

  Recruiting Phase 1 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT07572136

• A combination therapy for teens and young adults with relapsed or refractory T-ALL/T-LBL

  This phase 1 study tests a four-drug regimen (venetoclax, dexamethasone, bortezomib, and daratumumab) in adolescents and young adults whose T-cell ALL or T-cell lymphoblastic lymphoma has come back or not responded.

  Recruiting Phase 1 M.D. Anderson Cancer Center · Houston, Texas · NCT07513129

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.